Series A supercharges Superluminal’s GPCR mission

Superluminal Medicines, a US firm using generative biology, chemistry and machine learning in an attempt to revolutionize the speed and accuracy of how medicines are created, has closed a $120 million Series A funding round.

The funds will support the progression of Superluminal’s lead program into clinical development and increase the number of small molecule drug discovery programs focused on high-value G protein-coupled receptor (GPCR) targets. 

Superluminal’s platform rapidly creates candidate-ready compounds by using a unique combination of human understanding, generative biology, chemistry, machine learning and proprietary big data infrastructure.